article thumbnail

Tubeless automated insulin delivery system improves blood glucose outcomes

Scienmag

Study finds Omnipod® 5 simplifies diabetes management in type 1 diabetes WASHINGTON–People with type 1 diabetes can improve their blood sugar control while reducing time with low blood sugar, or hypoglycemia, using Insulet Corporation’s Omnipod 5 Automated Insulin Delivery System compared to their standard insulin therapy.

Insulin 71
article thumbnail

Controlling insulin production with a smartwatch

Scienmag

Credit: ETH Zurich Many modern fitness trackers and smartwatches feature integrated LEDs. The green light emitted, whether continuous or pulsed, penetrates the skin and can be used to measure the wearer’s heart rate during physical activity or while at rest. These watches have become extremely popular.

Insulin 95
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Patient Centricity in Insulin Delivery: Improving the Injection Experience with Droplet Micron

XTalks

The injection experience is an often-overlooked aspect in insulin administration. For many daily insulin users, the experience is an important one, as it is directly related to quality of life and medication compliance. Related: Droplet Micron Insulin Needle Offers Innovation in Crowded Diabetes Supply Market.

Insulin 64
article thumbnail

Enabling the next wave of innovative drug therapies with speciality enzymes

Pharmaceutical Technology

In 2021, Novo Nordisk Pharmatech, a leading pharmaceutical-grade insulin and Quats product supplier announced plans to enter the enzyme market. Novozymes has a long legacy of enzyme discovery and the ability to genetically engineer these speciality enzymes to be superior. Developing best-in-class speciality enzymes.

Drugs 295
article thumbnail

Islet transplantation with blood vessel cells shows promise to treat type 1 diabetes

Medical Xpress

Adding engineered human blood vessel-forming cells to islet transplants boosted the survival of the insulin-producing cells and reversed diabetes in a preclinical study led by Weill Cornell Medicine investigators.

Insulin 66
article thumbnail

Biocon buys Viatris biosimilars for $3.3bn, eyes IPO

pharmaphorum

Biocon’s partnership with Mylan – which merged with Pfizer’s Upjohn to form Viatris in 2020 – dates back more than a decade and has generated a number of biosimilars including insulin analogues, antibodies and recombinant proteins.

Insulin 102
article thumbnail

Biomaterial improves islet transplants for treatment of type 1 diabetes

Scienmag

The cells, taken from a donor pancreas, provide patients with a sustainable and tightly controlled source of insulin. Islet cell transplants are a promising treatment that can cure difficult-to-treat type 1 diabetes.

Insulin 84